Naotaka Hamasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Naotaka Hamasaki has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
S Kinoshita
Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka 812-8582
6 shared publicationsH Iida
5 shared publicationsSachiko Kinoshita
Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka
5 shared publicationsHiroko Iida
Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka
4 shared publicationsM Nakahara
4 shared publicationsMutsuko Nakahara
Department of Clinical Chemistry and Laboratory Medicine, Kyushu University Hospital, Fukuoka 812-8582, Japan
4 shared publications
Latest Publications
- 1 October 2018
- Published by Elsevier in Analytical Biochemistry
- Vol. 559, 91-93
Crystallization of Human Erythrocyte Band 3, the anion exchanger, at the International Space Station “KIBO”
- 1 October 2018
- Published by Elsevier in Analytical Biochemistry
- Vol. 559, 91-93
Crystallization of Human Erythrocyte Band 3, the anion exchanger, at the International Space Station “KIBO”
- 20 December 2002
- Published by Wiley in British Journal of Haematology
- Vol. 120 (1) , 101-108
Identification of simultaneous mutation of fibrinogen α chain and protein C genes in a Japanese kindred
Summary. Afibrinogenaemia usually induces a bleeding tendency during infancy, whereas protein C deficiency increases susceptibility to thrombosis in children or adolescence. Mutations of these genes have been, therefore, established as independent risk factors for coagulation disorders. We describe the homozygous mutation of the fibrinogen α chain gene and additional heterozygous mutation of the protein C gene in a male infant who showed prolonged umbilical bleeding after birth. On examination, the plasma fibrinogen was undetectable, and the activity and antigen level of protein C were reduced. The patient showed no fibrinogen Aα chain as well as Bβ and γ chains by Western blotting. The sequencing analysis showed the homozygous deletion of 1238 bases from intron 3 at position 2008 to intron 4 at position 3245 in the fibrinogen α chain gene. Both parents were heterozygous carriers of this mutation. In this patient, an additional mutation was also detected in the protein C gene: the heterozygous deletion of exon 7 at position 6161–6163 or 6164–6166, resulting the deletion of one amino acid (Lys150 or 151). His mother was also a carrier of this mutation. As the simultaneous mutation of the fibrinogen α chain and protein C genes has not been previously reported, the influence of the interaction between these two mutations on the clinical manifestations of this patient should be carefully monitored for a long period.
- 20 December 2002
- Published by Wiley in British Journal of Haematology
- Vol. 120 (1) , 101-108
Identification of simultaneous mutation of fibrinogen α chain and protein C genes in a Japanese kindred
Summary. Afibrinogenaemia usually induces a bleeding tendency during infancy, whereas protein C deficiency increases susceptibility to thrombosis in children or adolescence. Mutations of these genes have been, therefore, established as independent risk factors for coagulation disorders. We describe the homozygous mutation of the fibrinogen α chain gene and additional heterozygous mutation of the protein C gene in a male infant who showed prolonged umbilical bleeding after birth. On examination, the plasma fibrinogen was undetectable, and the activity and antigen level of protein C were reduced. The patient showed no fibrinogen Aα chain as well as Bβ and γ chains by Western blotting. The sequencing analysis showed the homozygous deletion of 1238 bases from intron 3 at position 2008 to intron 4 at position 3245 in the fibrinogen α chain gene. Both parents were heterozygous carriers of this mutation. In this patient, an additional mutation was also detected in the protein C gene: the heterozygous deletion of exon 7 at position 6161–6163 or 6164–6166, resulting the deletion of one amino acid (Lys150 or 151). His mother was also a carrier of this mutation. As the simultaneous mutation of the fibrinogen α chain and protein C genes has not been previously reported, the influence of the interaction between these two mutations on the clinical manifestations of this patient should be carefully monitored for a long period.
- 27 February 2002
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 41 (12) , 3852-3854
Flexible Regions within the Membrane-Embedded Portions of Polytopic Membrane Proteins
- 27 February 2002
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 41 (12) , 3852-3854
Flexible Regions within the Membrane-Embedded Portions of Polytopic Membrane Proteins
- 1 June 2001
- Vol. 53 (6) , 551-8
[Effects of preserved erythrocytes and activated-preserved erythrocytes with phosphoenolpyruvate on energy metabolism in rat ischemic brain tissue].
The effects of erythrocyte function on cerebral ischemia were studied from the perspective of filtration capability (deformability) and total oxygen delivery. Erythrocytes of Wistar rats were divided into three groups: fresh blood, preserved blood, and activated preserved blood (preserved erythrocytes in which total oxygen delivery was increased with phosphoenolpyruvate). Filtration capability was calculated and evaluated by a filtration technique, while total oxygen delivery was evaluated by calculating the efficiency of oxygen delivery from an oxygen dissociation curve. Exchange transfusion was performed in spontaneously hypertensive rats with each of these groups at the same hemoglobin concentration. Bilateral carotid arteries were then ligated for one hour, and, cerebral blood flow and concentrations of adenine nucleotide and lactic acid in cerebral tissue were measured. The filtration capability of both preserved blood and activated preserved blood decreased to about one-third that of fresh blood. The efficiency of oxygen delivery after blood transfusion decreased to 17% with preserved blood, which was about half that (35%) with fresh blood. In the group of with activated preserved blood, this rate increased to 52%. The adenylate energy charge (E.C.) in brain tissue markedly decreased to 0.27 with preserved blood, which was much lower than the value (0.74) with fresh blood. With activated preserved blood, the E.C. value was 0.39. Thus, the decrease in E.C. was mild. With regard to the lactic acid concentration in brain tissue, the value with fresh blood was 12 mumoles/g tissue, while that with preserved blood was 24 mumoles/g tissue, and that with activated preserved blood was 18 mumoles/g tissue. With respect to cerebral blood flow, the values with preserved blood and activated preserved blood decreased to about one-half that with fresh blood. These results suggest that an increase in total oxygen delivery by erythrocytes contributes to improving energy metabolism in brain tissue during cerebral ischemia, and particularly during poor microcirculation.
- 1 June 2001
- Vol. 53 (6) , 551-8
[Effects of preserved erythrocytes and activated-preserved erythrocytes with phosphoenolpyruvate on energy metabolism in rat ischemic brain tissue].
The effects of erythrocyte function on cerebral ischemia were studied from the perspective of filtration capability (deformability) and total oxygen delivery. Erythrocytes of Wistar rats were divided into three groups: fresh blood, preserved blood, and activated preserved blood (preserved erythrocytes in which total oxygen delivery was increased with phosphoenolpyruvate). Filtration capability was calculated and evaluated by a filtration technique, while total oxygen delivery was evaluated by calculating the efficiency of oxygen delivery from an oxygen dissociation curve. Exchange transfusion was performed in spontaneously hypertensive rats with each of these groups at the same hemoglobin concentration. Bilateral carotid arteries were then ligated for one hour, and, cerebral blood flow and concentrations of adenine nucleotide and lactic acid in cerebral tissue were measured. The filtration capability of both preserved blood and activated preserved blood decreased to about one-third that of fresh blood. The efficiency of oxygen delivery after blood transfusion decreased to 17% with preserved blood, which was about half that (35%) with fresh blood. In the group of with activated preserved blood, this rate increased to 52%. The adenylate energy charge (E.C.) in brain tissue markedly decreased to 0.27 with preserved blood, which was much lower than the value (0.74) with fresh blood. With activated preserved blood, the E.C. value was 0.39. Thus, the decrease in E.C. was mild. With regard to the lactic acid concentration in brain tissue, the value with fresh blood was 12 mumoles/g tissue, while that with preserved blood was 24 mumoles/g tissue, and that with activated preserved blood was 18 mumoles/g tissue. With respect to cerebral blood flow, the values with preserved blood and activated preserved blood decreased to about one-half that with fresh blood. These results suggest that an increase in total oxygen delivery by erythrocytes contributes to improving energy metabolism in brain tissue during cerebral ischemia, and particularly during poor microcirculation.
- 1 May 2001
- Published by Elsevier in Thrombosis Research
- Vol. 102 (3) , 187-196
Failure in the Detection of Aberrant mRNA from the Heterozygotic Splice Site Mutant Allele for Protein S in a Patient with Protein S Deficiency
- 1 May 2001
- Published by Elsevier in Thrombosis Research
- Vol. 102 (3) , 187-196
Failure in the Detection of Aberrant mRNA from the Heterozygotic Splice Site Mutant Allele for Protein S in a Patient with Protein S Deficiency
- 1 May 2001
- Vol. 49 (5) , 512-21
[Clinical laboratory data and reference intervals standardized in Fukuoka].
In Fukuoka whose population is approximately five million inhabitants, surveys on the accuracy of laboratory data have been performed by the Fukuoka Prefecture Medical Association for the last 30 years. We have been attempting to evaluate the data for routine use since 1988, and it has become possible to share laboratory data between all institutions in Fukuoka prefectures. As a result, reference intervals for 23 clinical chemistry analytes were established in 1995, to which were added in 1996 five serum protein constituents that have been utilized for clinical examinations. Methods for documentations and monitorings the data obtained in the prefecture were also established, standardization of the above analytes extended to 97% of the institutions in the prefecture. Results for 14 of the 23 clinical chemistry analytes have become highly reliable and clinically useful as differences between institutions in terms of results have narrowed. Standardization of other analytes is now in progress.
- 1 May 2001
- Vol. 49 (5) , 512-21
[Clinical laboratory data and reference intervals standardized in Fukuoka].
In Fukuoka whose population is approximately five million inhabitants, surveys on the accuracy of laboratory data have been performed by the Fukuoka Prefecture Medical Association for the last 30 years. We have been attempting to evaluate the data for routine use since 1988, and it has become possible to share laboratory data between all institutions in Fukuoka prefectures. As a result, reference intervals for 23 clinical chemistry analytes were established in 1995, to which were added in 1996 five serum protein constituents that have been utilized for clinical examinations. Methods for documentations and monitorings the data obtained in the prefecture were also established, standardization of the above analytes extended to 97% of the institutions in the prefecture. Results for 14 of the 23 clinical chemistry analytes have become highly reliable and clinically useful as differences between institutions in terms of results have narrowed. Standardization of other analytes is now in progress.
- 1 February 2001
- Vol. 49 (2) , 165-71
[Genetic polymorphism and risk of thromboses].
We have attempted to establish a systematic pathogenetic analysis of thrombophilia by including assays of antithrombin III(AT III), protein C(PC), protein S(PS), fibrinogen, plasminogen and heparin cofactor II by both functional and immunological methods as well as detecting lupus anticoagulants. Such a comprehensive scheme was instrumental in systematically identifying and confirming the pathogenesis of 164 cases which otherwise would have escaped detection since 1994 in our laboratory (Kyushu University Hospital). The analysis was conducted on 485 consecutive patients with venous thrombosis, arterial thrombosis and disorders in which small vessel thrombosis were implicated. Hundred and sixty four patients, (40% of the examined patients), were found to have low activities of PS, PC, ATIII etc. Among them, seventy five patients(46%) had low PS activity, and twenty nine(18%) had low PC activity. Genetic analyses performed on specimens with low PS/PC activities resulted in the confirmation of 24 genetic abnormalities. Such genetic abnormalities, however, does not solely lead to the pathogenesis of thromboses. We have found that some genetic polymorphisms, such as PS Tokushima, factor XII 46C allele, were also additional risk factors for thromboses.
- 1 February 2001
- Vol. 49 (2) , 165-71
[Genetic polymorphism and risk of thromboses].
We have attempted to establish a systematic pathogenetic analysis of thrombophilia by including assays of antithrombin III(AT III), protein C(PC), protein S(PS), fibrinogen, plasminogen and heparin cofactor II by both functional and immunological methods as well as detecting lupus anticoagulants. Such a comprehensive scheme was instrumental in systematically identifying and confirming the pathogenesis of 164 cases which otherwise would have escaped detection since 1994 in our laboratory (Kyushu University Hospital). The analysis was conducted on 485 consecutive patients with venous thrombosis, arterial thrombosis and disorders in which small vessel thrombosis were implicated. Hundred and sixty four patients, (40% of the examined patients), were found to have low activities of PS, PC, ATIII etc. Among them, seventy five patients(46%) had low PS activity, and twenty nine(18%) had low PC activity. Genetic analyses performed on specimens with low PS/PC activities resulted in the confirmation of 24 genetic abnormalities. Such genetic abnormalities, however, does not solely lead to the pathogenesis of thromboses. We have found that some genetic polymorphisms, such as PS Tokushima, factor XII 46C allele, were also additional risk factors for thromboses.
- 1 January 2001
- Vol. 49 (1) , 9-18
[Molecular biology techniques as clinical laboratory tests].
The quality of results obtained with molecular biology techniques depends on the control of preanalytical and analytical error associated with such techniques. Preanalytical error can be introduced during the isolation of DNA and RNA. The type of detergent used in cell lysis can affect the amplification of DNA by techniques such as the polymerase chain reaction(PCR). Ribonuclease(RNase) contamination is a serious problem in the isolation of undegraded RNA, and, thus, this enzyme should be inhibited. Anticoagulants used for blood collection can affect the quality of results with molecular biology techniques. The control of contamination from the working environment is essential to the minimization of preanalytical, analytical and postanalytical error. Molecular biology techniques for a wide range of clinical laboratory tests have been established in hospitals such as clinical laboratory tests for infections, molecular diagnoses of leukemia and aberrant genes in metabolism.
- 1 January 2001
- Vol. 49 (1) , 9-18
[Molecular biology techniques as clinical laboratory tests].
The quality of results obtained with molecular biology techniques depends on the control of preanalytical and analytical error associated with such techniques. Preanalytical error can be introduced during the isolation of DNA and RNA. The type of detergent used in cell lysis can affect the amplification of DNA by techniques such as the polymerase chain reaction(PCR). Ribonuclease(RNase) contamination is a serious problem in the isolation of undegraded RNA, and, thus, this enzyme should be inhibited. Anticoagulants used for blood collection can affect the quality of results with molecular biology techniques. The control of contamination from the working environment is essential to the minimization of preanalytical, analytical and postanalytical error. Molecular biology techniques for a wide range of clinical laboratory tests have been established in hospitals such as clinical laboratory tests for infections, molecular diagnoses of leukemia and aberrant genes in metabolism.
- 1 December 2000
- Published by Wiley in Vox Sanguinis
- Vol. 79 (4) , 191-197
Red Blood Cell Function and Blood Storage
Red blood cells are ideal vehicles for delivering oxygen to tissues, but their functions deteriorate during liquid preservation. In this article, we review the role of red blood cells in oxygen delivery and methods to evaluate the effectiveness of red blood cell transfusion. Quantitative estimation of transfusion effects could avoid unnecessary transfusion and reduce the risk of transfusion‐associated disorders. We also describe the benefits of transfusion of red blood cells having a higher oxygen‐delivering capacity. Phosphoenolpyruvate is a promising component to prepare red blood cells having a higher oxygen‐delivering capacity.
- 1 December 2000
- Published by Wiley in Vox Sanguinis
- Vol. 79 (4) , 191-197
Red Blood Cell Function and Blood Storage
Red blood cells are ideal vehicles for delivering oxygen to tissues, but their functions deteriorate during liquid preservation. In this article, we review the role of red blood cells in oxygen delivery and methods to evaluate the effectiveness of red blood cell transfusion. Quantitative estimation of transfusion effects could avoid unnecessary transfusion and reduce the risk of transfusion‐associated disorders. We also describe the benefits of transfusion of red blood cells having a higher oxygen‐delivering capacity. Phosphoenolpyruvate is a promising component to prepare red blood cells having a higher oxygen‐delivering capacity.
- 1 July 2000
- Vol. 84 (1) , 49-53
A case of congenital afibrinogenemia: fibrinogen Hakata, a novel nonsense mutation of the fibrinogen gamma-chain gene.
Congenital afibrinogenemia due to a novel homozygous nonsense mutation of the fibrinogen gamma-chain gene, fibrinogen Hakata, was found in an 18-year-old Japanese girl who had received supplemental fibrinogen therapy since she was 4 months old. The plasma fibrinogen concentrations of the proband were measured as less than 10 mg/dl by a functional method and less than 17 mg/dl by an immunological method. Fibrinogen concentrations of her family were in the range of 94-164 mg/dl. The proband and her family had no other clinical symptoms. Genomic DNA of the proband and her family was isolated from leukocytes, and all exons of fibrinogen subunits and their intron/exon boundaries were analyzed. A genetic mutation, a guanine-to-thymine (G-to-T) transversion at the nucleotide position of 5860, was identified on exon 7 of the gamma-chain gene. This mutation changed the codon for the 231st residue of the gamma-chain from GAG (Glu) to TAG (stop). No other mutation was observed. Aalpha, Bbeta and gamma chains were observed in plasma of the heterozygous family members. However, only a trace amount of Aalpha chain and no gamma chain was detected in the plasma of the proband.
- 1 July 2000
- Vol. 84 (1) , 49-53
A case of congenital afibrinogenemia: fibrinogen Hakata, a novel nonsense mutation of the fibrinogen gamma-chain gene.
Congenital afibrinogenemia due to a novel homozygous nonsense mutation of the fibrinogen gamma-chain gene, fibrinogen Hakata, was found in an 18-year-old Japanese girl who had received supplemental fibrinogen therapy since she was 4 months old. The plasma fibrinogen concentrations of the proband were measured as less than 10 mg/dl by a functional method and less than 17 mg/dl by an immunological method. Fibrinogen concentrations of her family were in the range of 94-164 mg/dl. The proband and her family had no other clinical symptoms. Genomic DNA of the proband and her family was isolated from leukocytes, and all exons of fibrinogen subunits and their intron/exon boundaries were analyzed. A genetic mutation, a guanine-to-thymine (G-to-T) transversion at the nucleotide position of 5860, was identified on exon 7 of the gamma-chain gene. This mutation changed the codon for the 231st residue of the gamma-chain from GAG (Glu) to TAG (stop). No other mutation was observed. Aalpha, Bbeta and gamma chains were observed in plasma of the heterozygous family members. However, only a trace amount of Aalpha chain and no gamma chain was detected in the plasma of the proband.